January 20, 2022
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
January 6, 2022
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors